Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J , May 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2019 and provided an update

LAWRENCEVILLE, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox ® , its

  Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox ®           Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J , April 17, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical stage oncology drug

   Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and  its Phase I/II Clinical Study in Ovarian Cancer LAWRENCEVILLE, N.J. , April 12, 2019 (GLOBE NEWSWIRE) --   Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael

LAWRENCEVILLE, N.J. , April 12, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox®, its

Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline  Company to Hold Conference Call on Friday, March 29, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , March 29, 2019 (GLOBE NEWSWIRE) --   Celsion Corporation (NASDAQ: CLSN), an oncology

LAWRENCEVILLE, N.J , March 22, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary

100% Objective Response Rates and 88% Complete (R0) Resection Rates in Highest Dose Cohorts GEN-1 Intraperitoneally Delivered Durable Local Levels of Pro-Immune IL-12 and Related Cytokines Dose Dependent Reduction in Immunosuppressive Biomarkers Suggest Positive Effect on Tumor Microenvironment

LAWRENCEVILLE, N.J. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019 , the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the

LAWRENCEVILLE, N.J. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church , Celsion’s Executive Vice President and Chief Financial Officer, will present at NobleConXV - Noble Capital Markets’ 15 th Annual